Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

7.240 +0.470 (+6.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,087,442
Open 6.830
Bid (Size) 7.030 (10)
Ask (Size) 7.510 (5)
Prev. Close 6.770
Today's Range 6.490 - 7.240
52wk Range 5.720 - 37.98
Shares Outstanding 71,829,718
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 10 Analyst Ratings Have To Say About Revance Therapeutics
Via Benzinga
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. 
Via Benzinga

Performance

YTD
-60.57%
-60.57%
1 Month
-14.22%
-14.22%
3 Month
-58.60%
-58.60%
6 Month
-76.78%
-76.78%
1 Year
-67.31%
-67.31%

More News

Read More
AerSale, Topgolf Callaway Brands, Digital Turbine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Revance Therapeutics: Q3 Earnings Insights
Via Benzinga
Revance Therapeutics's Earnings Outlook
Via Benzinga
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
From Revance Therapeutics, Inc.
Via Business Wire
The Latest Analyst Ratings for Revance Therapeutics
Via Benzinga
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Analyst Ratings for Revance Therapeutics
Via Benzinga
The Latest Analyst Ratings for Revance Therapeutics
Via Benzinga
What's Going On With Botox Rival Revance Therapeutics' Stock Today?
Via Benzinga
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From Revance Therapeutics, Inc.
Via Business Wire
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
From Revance Therapeutics, Inc.
Via Business Wire
Discontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In Millions
Via Benzinga
Pinterest To Rally Around 45%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Instacart, ARS Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Dow Falls 150 Points; AutoZone Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Crude Oil Rises Over 1%; Revance Therapeutics Shares Plummet
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke
Via Investor's Business Daily
Markets Open Lower; US Housing Starts Fall In August
Via Benzinga
Topics Stocks
Exposures US Equities
Revance Provides Corporate Update at Investor Day
From Revance Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.